US EditionAlvogen Completes Comprehensive Refinancing
- Alvogen Pharma US, Inc. Has successfully completed a comprehensive refinancing of its capital structure on March 7, 2025.
- Alvogen raised $553 million from a first lien term loan due 2028 and $116 million from a second lien term loan due 2029.
- Goldman Sachs & Co. LLC and Jefferies LLC acted as financial advisors for Alvogen's refinancing transaction.
- Lisa Graver, Chief Executive Officer of Alvogen, stated, 'We are pleased to have completed this important refinancing for Alvogen,' emphasizing improved liquidity and strategic flexibility.
Insights by Ground AI
Does this summary seem wrong?
28 Articles
28 Articles
All
Left
2
Center
11
Right
2
Coverage Details
Total News Sources28
Leaning Left2Leaning Right2Center11Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
13%
C 73%
13%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
